Insulin Lispro
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Insulin Lispro: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin lispro is a rapid-acting insulin analog originally used to achieve glycemic control in diabetes mellitus. The TxGNN model predicts a possible link to Autoimmune Oophoritis, but this pairing currently has zero clinical trials and zero publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes mellitus (glycemic control) — general drug-class knowledge; no New Zealand license text is available to confirm the exact approved wording |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, insulin lispro is a rapid-acting insulin analog used for insulin replacement therapy, and its efficacy in diabetes mellitus is well established; mechanistically, insulin/IGF signaling could in theory intersect with ovarian follicular and immune biology, which is the likely basis for the model's association.
However, this same evidence pack flags a cluster of adjacent low-confidence predictions for this drug — classic stiff person syndrome, focal stiff limb syndrome, centrifugal lipodystrophy, and pressure-induced localized lipoatrophy — as probable false positives caused by the knowledge graph confusing disease co-morbidity with a direct treatment relationship (e.g., insulin is used to manage co-existing type 1 diabetes in stiff-person-syndrome patients, not to treat the syndrome itself; lipodystrophy/lipoatrophy are actually known adverse effects of insulin injection, not indications for it). Autoimmune oophoritis shares the same risk profile: it is an autoimmune endocrine disease that can co-occur with autoimmune (type 1) diabetes, so the high score plausibly reflects shared patient population/co-morbidity rather than a genuine pharmacological effect of insulin on ovarian autoimmunity. No mechanistic or clinical data currently distinguish these possibilities.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Insulin lispro is not currently marketed in New Zealand (Medsafe status: not marketed); no authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted pairing has no clinical trial or literature support (L5, model prediction only), the drug is not marketed in New Zealand, and safety/label data are entirely unavailable (a Blocking data gap that prevents even an initial S1 safety screen). There is no basis to advance this candidate at this time.
To proceed, the following is needed:
- TFDA/Medsafe package insert — warnings, contraindications (DG001, Blocking; currently prevents S1 safety evaluation)
- Verified mechanism of action data (DG002, High)
- Any preclinical or mechanistic evidence linking insulin signaling to autoimmune oophoritis specifically (not just diabetes co-morbidity)
- Confirmation of whether the TxGNN signal reflects a true treatment effect versus disease co-occurrence bias, given the same pattern was flagged as likely false-positive for related predictions in this drug's own evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.